durvalumab,niraparib,avelumab,enfortumab vedotin
janssen,pfizer,seagen,astellas,merck,astrazeneca,gsk
['blcsm', 'mibc', 'avelumab', 'ev-301', 'magnitude', 'muc ,(-much)', 'sakk 06/17']
#blcsm poster discussions #asco22: 1) phii sakk 06/17 periop durva + chemo #pcr 34% #mibc, 2) avelumab monotx 36% #pcr vs avelumab + gem/taxane 18% #pcr in cis-ineligible #mibc, 3) ev-301 long-term follow-up sustains magnitude of benefit in #muc 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope